Filing Flows › Dianthus Therapeutics (DNTH) › R&D spending
Dianthus Therapeutics (DNTH) R&D spending by quarter
Dianthus Therapeutics' R&D spending was $59.9M in Q4 2025 (fourth quarter 2025), +84% from Q3 2025. Over the last 5 quarters it ranged from $26.3M (Q2 2025) to $59.9M (Q4 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q4 2025 | $59.9M | +84% | +127% |
| Q3 2025 | $32.5M | +24% | — |
| Q2 2025 | $26.3M | -3% | — |
| Q1 2025 | $27.0M | +2% | — |
| Q4 2024 | $26.4M | — | — |
Q4 2025 at a glance
Dianthus Therapeutics, Q4 2025: revenue $284K (-79% year over year), net loss $64.4M, operating cash flow −$47.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is Dianthus Therapeutics' R&D spending?
Dianthus Therapeutics' R&D spending was $59.9M in Q4 2025 (fourth quarter 2025), +84% from Q3 2025.
How has Dianthus Therapeutics' R&D spending changed?
Over the last 5 quarters it ranged from $26.3M (Q2 2025) to $59.9M (Q4 2025).